Abstract

PHARMACOLOGICAL ACTIVITIES OF MICROSPHERE DRUG USED IN HIV: REVIEW

Deepak Kumar*, Ankit Kumar (M. Pharma), Suryakant Verma and Dr. Sachin Tyagi

ABSTRACT

Until recently, alpha-interferon was the only widely accepted treatment for chronic hepatitis B, but its effectiveness in sustained response was only modest (biochemical, virological and histological). Only 20% to 40% of the patients treated reacting to therapy, with a lower percentage (~10%) of the patients infected with HBV precore strains (HBeAb HBV-DNA positive). The US FDA approved the use of lamivudine in adult chronic hepatitis B patients in 1998. In this study, we concentrated on the pharmacokinetic and pharmacodynamically effective and tolerable properties of lamivudine for both HBeAg and HBe-positive chronic hepatitis B instances.

Keywords: Heptatitis, Hiv, Microshere, Epivir.